Consistent with a specific vulnerability of EGFR-addicted cancer cells to sorafenib, gene expression analysis of tumor samples from various independent clinical trials indicates that patient response to this drug is significantly correlated with a high EGFR transcriptional score. The gene discussed is EGFR; the disease is neoplasm.